Trial
NCT02907619
An Open-label Extension Study To Evaluate Safety Of PF-06252616 In Boys With Duchenne Muscular Dystrophy
Phase IITERMINATEDEFFICACY/FUTILITYConfidence: MEDIUM
Sponsor
Pfizer
Collaborators
—
Condition
Duchenne Muscular Dystrophy
Intervention
PF-06252616
Why stopped
Termination Date: 30Aug2018; Reason for termination: Lack of Efficacy
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2020-11-23